Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00004354 |
Recruitment Status
:
Completed
First Posted
: October 19, 1999
Last Update Posted
: June 24, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
OBJECTIVES: I. Determine the prevalence of glucocorticoid-remediable aldosteronism (GRA) in various hypertensive populations and screen at risk members of GRA pedigrees.
II. Investigate other factors regulating blood pressure in GRA (environmental, genetically determined factors).
III. Investigate renal and hormonal mechanisms regulating potassium homeostasis in GRA.
IV. Describe clinical phenotype of GRA patients. V. Prospectively screen GRA-affected patients with MRI angiography for intracranial aneurysm.
Condition or disease |
---|
Hyperaldosteronism |
PROTOCOL OUTLINE:
Patients are screened for high blood pressure, suppressed plasma renin activity level, and low potassium levels. Urine is collected for a 24 hour period. Blood specimen is collected for molecular biologic evaluation for the presence of the chimeric gene diagnostic of GRA. Any history of cardiovascular events is recorded.
Study Type : | Observational |
Primary Purpose: | Screening |
Study Start Date : | June 1999 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Diagnosed glucocorticoid-remediable aldosteronism (GRA) with hypertension Hypokalemia is variably seen Blood pressure variably elevated Elevated level of aldosterone Low level of plasma renin activity

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004354
United States, Massachusetts | |
Brigham and Women's Hospital | |
Boston, Massachusetts, United States, 02115 |
Study Chair: | Robert G. Dluhy | Brigham and Women's Hospital |
ClinicalTrials.gov Identifier: | NCT00004354 History of Changes |
Other Study ID Numbers: |
199/11917 BWH-91328603 |
First Posted: | October 19, 1999 Key Record Dates |
Last Update Posted: | June 24, 2005 |
Last Verified: | May 2002 |
Keywords provided by National Center for Research Resources (NCRR):
endocrine disorders genetic diseases and dysmorphic syndromes hyperaldosteronism rare disease |
Additional relevant MeSH terms:
Hyperaldosteronism Adrenocortical Hyperfunction Adrenal Gland Diseases Endocrine System Diseases |